Schedule an Appointment
Select Page
By Stephen L. Rose, MD


Breast tomosynthesis is a new method for breast cancer screening and diagnosis. Unlike prior-generation mammography systems, which generate 2-dimensional images, breast tomosynthesis produces 3-dimensional
images, which are intended to reveal the inner architecture of the breast free from the superimposition of overlying structures. While tomosynthesis can be acquired independently, a screening examination, as required by the U.S. Food and Drug Administration (FDA), includes a tomosynthesis data set in combination with a 2-dimensional image. The perfectly registered images take only seconds longer to acquire than a conventional 2-dimensional digital mammogram at a total exam dose within current FDA guidelines for screening mammography.
A tomosynthesis scan virtually eliminates detection challenges associated with overlapping structures in the breast, which is the primary drawback of conventional 2-dimensional analog and digital mammography. In addition, breast tomosynthesis offers other potential benefits, including increased lesion and margin visibility, help in localizing structures in the breast, a reduction in recall rates, and increased cancer detection.

Patient Information

A 42-year-old female presents for a routine screening mammogram.

Imaging Findings

A 2-dimensional mammogram shows no suspicious findings. Upon review of the tomosynthesis data set, a 7-mm spiculated mass was detected in the upper outer quadrant of the left breast at 2 o’clock. Ultrasound confirmed the presence of a suspicious mass at 2 o’clock measuring 7 mm.


T1b, N0, M0 stage 1A invasive ductal carcinoma.


Lumpectomy with radiation. No chemotherapy.


The use of tomosynthesis in the screening setting was essential for the early diagnosis in this patient. The tumor is imperceptible on standard 2-dimensional imaging, however, the tomosynthesis slices demonstrate a spiculated mass because of the ability to peel away the superimposing tissue that obscures the distortion on the 2-dimensional images. This can be seen clearly on both MLO and CC projections. We have seen a reduction in call back rates for additional testing by approximately 50%, while increasing our detection of very early cancers.The ultrasound exam confirms the presence of a small lesion at 2 o’clock in the left breast. An ultrasound-guided biopsy was performed documenting a 7-mm infiltrating ductal carcinoma. Early detection of breast cancer is associated with decreased mortality and reduced morbidity.
It is unclear when or if this cancer would be revealed on future 2-dimensional mammography in this heterogeneously dense breast or if it would have only been discovered as a palpable finding at a much later stage in the disease process. In addition to the drawbacks of dimensional imaging, many women, especially in their 40’s, do not get yearly mammograms, therefore, we would miss any opportunity to detect this cancer before it.


Tomosynthesis is a revolutionary new approach to screening for breast cancer. In our practice, we have seen a reduction in call back rates for additional testing by approximately 50%, while increasing our detection of very early cancers. Our practice has performed over 10,000 screening tomosynthesis exams and is currently doing an evaluation of 2-dimensional exams read alone versus the combination of 2- dimensional/tomosynthesis exams. Initial results are extremely encouraging. Our data on call back rates match those reported by others using tomosynthesis in the screening environment.
“I think tomosynthesis is a practical solution because unlike some modalities,” said Dr. Rose, “tomosynthesis is easy to use and efficient, enabling us to screen almost everyone.”
The views and opinions expressed in this clinical case review are the opinions of the author and do not necessarily reflect the views and opinions of the sponsoring company. This article is intended for medical professionals and/or specific product users residing in the United States and other countries and should not be considered as a solicitation or promotion of any product or of an indication of any product that is not authorized by the laws and regulations of another country where the reader resides. This article could refer to products that are or may not be available in any particular country, and/or may not have received market clearance by a governmental regulatory body for indications and restrictions in different countries.
Tomosynthesis, revolutionary screening for breast cancer - XRAMN


  • Gullien R, Eben E, Ekseth U, et al. Reading time of FFDM and tomosynthesis in a population-based screening program. RSNA 2011. Breast series: Emerging technologies in breast imaging. MSVB31-07. cfm?printmode=n&em_id=11011027. Updated November 29, 2011. Accessed March 13, 2012.
  • Tabár L, Vitak B, Chen TH, et al. Swedish two-county trial: Impact of mammographic screening on breast cancer mortality during 3 decades. Radiology. 2011;260:658-663. Epub 2011 Jun 28.
Dr. Rose is Medical Director of the Tops Comprehensive Breast Center, Houston, TX, and President and Founder.

of Houston Breast Imaging, Houston, TX